Dr. Qiang Zhang received his Bachelor’s degree in Beijing Medical College in 1982 and received his Ph.D degree at West China University of Medical Sciences in 1995. After working in Sichuan Industrial Institute of Antibiotics for 10 years, in 1995 he moved to School of Pharm. Sci., Peking University where he was promoted to Associated Professor in 1996 and Professor in 1999. He began his study in nanomedicine in 1992 when reading for Ph.D degree. Now more than 300 SCI papers were published, which was highly cited, garnered numerous awards, and boosted related pharmaceutics research. As the DDS people, he have developed serial DDS into market and some others into clinical study. One of them has become the star product of a major domestic pharmaceutical company, having brought in significant economic and social benefits.
Currently he is the Honor Chair of Pharmaceutics Committee of Chinese Pharmaceutical Association (CPA), Founder and Vice-Chair of Nanomedicines Committee of CPA, Vice-Chair of Pharmaceutics Committee of Chinese Pharmacopoeia, Expert for Center of Drug Evaluation of CFDA, the first Editorial board member of J Controlled Release in China, and so on. He was also the first President of CRS-China Chapter and the Vice-Dean of School of Pharm. Sci., Peking University.
Research Interests: Molecular Pharmaceutics and the translational study on novel DDS, including the mechanism and translational studies on novel drug delivery systems for water-insoluble drugs, antitumor drugs and biotechnology drugs.